Rigel Pharma (RIGL) Misses Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $48.67 +0.35%
Revenue Growth %: +15.2%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +15.2%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q2 EPS of ($0.06), $0.04 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $36.84 million versus the consensus estimate of $33.7 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- Nomura/Instinet Upgrades MR DIY Group M Bhd (MRDIY:MK) to Buy
- UBS Upgrades E.ON SE (EOAN:GR) (EONGY) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
